The diagnosis and medical management of advanced neuroendocrine tumors.
The DOI matches its Crossref record; 657 of the 670 references it cites were found in a registry or an index.
Abstract
Neuroendocrine tumors (NETs) constitute a heterogeneous group of neoplasms that originate from endocrine glands such as the pituitary, the parathyroids, and the (neuroendocrine) adrenal, as well as endocrine islets within glandular tissue (thyroid or pancreatic) and cells dispersed between exocrine cells, such as endocrine cells of the digestive (gastroenteropancreatic) and respiratory tracts. Conventionally, NETs may present with a wide variety of functional or nonfunctional endocrine syndromes and may be familial and have other associated tumors. Assessment of specific or general tumor markers offers high sensitivity in establishing the diagnosis and can also have prognostic significance. Imaging modalities include endoscopic ultrasonography, computed tomography and magnetic resonance imaging, and particularly, scintigraphy with somatostatin analogs and metaiodobenzylguanidine. Successful treatment of disseminated NETs requires a multimodal approach; radical tumor surgery may be curative but is rarely possible. Well-differentiated and slow-growing gastroenteropancreatic tumors should be treated with somatostatin analogs or alpha-interferon, with chemotherapy being reserved for poorly differentiated and progressive tumors. Therapy with radionuclides may be used for tumors exhibiting uptake to a diagnostic scan, either after surgery to eradicate microscopic residual disease or later if conventional treatment or biotherapy fails. Maintenance of the quality of life should be a priority, particularly because patients with disseminated disease may experience prolonged survival.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“With the combination of noninvasive and selected invasive modalities (particularly endoscopic ultrasound), most insulinomas are localized preoperatively (72, 78).”
From Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline (2009) · cites this paper as [72]
In the citing paper
“Although the results with a given method reflect the experience and expertise with that method at a given center, computed tomography, MRI, and transabdominal ultrasonography detect most insulinomas (71-73).”
From Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline (2009) · cites this paper as [72]
Citations
Cites
Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death
Hockenbery, D., Nuñez, G., Milliman, C., Schreiber, R. D., & Korsmeyer, S. J. (1990) · Nature · doi:10.1038/348334a0 · Cited by 3,720
Induction of apoptosis in fibroblasts by c-myc protein
Evan, G. I., Wyllie, A. H., Gilbert, C. S., Littlewood, T. D., Land, H., Brooks, M., Waters, C. M., Penn, L. Z., & Hancock, D. C. (1992) · Cell · doi:10.1016/0092-8674(92)90123-t · Cited by 2,935
A 5‐decade analysis of 13,715 carcinoid tumors
Modlin, I. M., Lye, K. D., & Kidd, M. (2003) · Cancer · doi:10.1002/cncr.11105 · Cited by 2,734
CONSENSUS: Guidelines for Diagnosis and Therapy of MEN Type 1 and Type 2
Brandi, M. L. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.12.5658 · Cited by 2,031
Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A
Mulligan, L. M., Kwok, J. B. J., Healey, C. S., Elsdon, M. J., Eng, C., Gardner, E., Love, D. R., Mole, S. E., Moore, J. K., Papi, L., et al. (1993) · Nature · doi:10.1038/363458a0 · Cited by 1,966
Mutations in SDHD , a Mitochondrial Complex II Gene, in Hereditary Paraganglioma
Baysal, B. E., Ferrell, R. E., Willett-Brozick, J. E., Lawrence, E. C., Myssiorek, D., Bosch, A., Mey, A. V. D., Taschner, P. E. M., Rubinstein, W. S., Myers, E. N., et al. (2000) · Science · doi:10.1126/science.287.5454.848 · Cited by 1,638
Krenning, E. P., Kwekkeboom, D. J., Bakker, W. H., Breeman, W. A. P., Kooij, P. P. M., Oei, H. Y., van Hagen, M., Postema, P. T. E., de Jong, M., Reubi, J. C., et al. (1993) · European Journal of Nuclear Medicine · doi:10.1007/bf00181765 · Cited by 1,564
Gutmann, D. H. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03550010065042 · Cited by 1,359
An analysis of 8305 cases of carcinoid tumors
Modlin, I. M., & Sandor, A. (2000) · Cancer · doi:10.1002/(sici)1097-0142(19970215)79:4<813::aid-cncr19>3.0.co;2-2 · Cited by 1,200
The Complex of Myxomas, Spotty Pigmentation, and Endocrine Overactivity
CARNEY, J. A., GORDON, H., CARPENTER, P. C., SHENOY, B. V., & W. GO, V. L. (1985) · Medicine · doi:10.1097/00005792-198507000-00007 · Cited by 1,114
Research works printed but not linked: 3
- Krenning, 1994, Essentials of peptide receptor scintigraphy with emphasis on the somatostatin analog octreotide., Semin Oncol, 21, 6
- Janson, 2000, Nuclear localization of 111In after intravenous injection of [111In-DTPA-D-Phe1]-octreotide in patients with neuroendocrine tumors., J Nucl Med, 41, 1514
- Bartsch, 1990, Treatment of metastatic carcinoid tumors by recombinant human interferon-α. Results from a phase II study., J Cancer Res Clin Oncol, 116, 305
Cited by
Items 201–300 of 679
Chakedis, J. M., Beal, E. W., Lopez‐Aguiar, A. G., Poultsides, G. A., Makris, E. A., Rocha, F. G., Kanji, Z. S., Weber, S. M., Fisher, A. V., Fields, R. C., et al. (2018) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-018-3986-4 · Cited by 29
Pancreatic neuroendocrine tumors
Muniraj, T., Vignesh, S., Shetty, S. S., Thiruvengadam, S., & Aslanian, H. R. (2013) · Disease-a-Month · doi:10.1016/j.disamonth.2012.10.002 · Cited by 33
Lim, T., Jeeyun, L. E. E., Kim, J. J., Lee, J. K., Lee, K. T., Kim, Y. H., Kwang‐Won, K. I. M., Kim, S. H., Sohn, T. S., Choi, D. W., et al. (2011) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/j.1743-7563.2011.01423.x · Cited by 28
Kennedy, A. S., Coldwell, D. M., Sangro, B., Wasan, H. S., & Salem, R. (2011) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e3182005768 · Cited by 28
“Moreover, most NETs are associated with the carcinoid syndrome: a combination of diarrhea, flush, bronchoconstriction (wheezing), and right valvular heart failure.(33,34) Palliative debulking of the tumor is not only necessary to relieve symptoms, but may also improve survival for patients with liver metastases.”
Backgroundde Herder, W. W. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0077 · Cited by 30
Tsoukalas, N., Chatzellis, E., Rontogianni, D. P., Alexandraki, K., Boutzios, G., Angelousi, A. G., & Kaltsas, G. (2017) · Medicine · doi:10.1097/md.0000000000006201 · Cited by 30
Self-citationRetroperitoneal non-functioning paraganglioma: A difficult tumour to diagnose and treat
Gannan, E., van Veenendaal, P., Scarlett, A., & Ng, M. K. (2015) · International Journal of Surgery Case Reports · doi:10.1016/j.ijscr.2015.11.004 · Cited by 27
Shi, H., Jiang, C., Zhang, Q., Qi, C., Yao, H., & Lin, R. (2020) · Diagnostic Pathology · doi:10.1186/s13000-020-01030-x · Cited by 28
Antisecretory factor as a potential health-promoting molecule in man and animals
Ulgheri, C., Paganini, B., & Rossi, F. (2010) · Nutrition Research Reviews · doi:10.1017/s0954422410000193 · Cited by 27
“Medullary thyroid carcinoma is a neuroendocrine tumour that develops in the thyroid C cells and occurs either as an erratic event or secondary to a germline mutation with an autosomal dominant pattern of inheritance((90)).”
Extrapulmonary Neuroendocrine Carcinomas: Current Management and Future Perspectives
Stumpo, S., Formelli, M. G., Persano, I., Parlagreco, E., Lauricella, E., Rodriquenz, M. G., Guerrera, L. P., Zurlo, I. V., Campana, D., Brizzi, M. P., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12247715 · Cited by 26
Future clinical prospects in somatostatin/cortistatin/somatostatin receptor field
Dalm, V. A. S. H., Hofland, L. J., & Lamberts, S. W. J. (2007) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2007.09.005 · Cited by 26
“It may prevent surgery with curative intent in patients with metastatic disease and it may select patients applicable for treatment with SS analogues or with tumour targeted radioactive treatment using radiolabeled SS analogues (Jamar et al., 1995; Kaltsas et al., 2004; Krenning et al., 1994a; Krenning et al., 1994b;…”
BackgroundInfluentialDiagnosis and management of small bowel neuroendocrine tumors: A state-of-the-art
Yovera, J. G. G., Roseboom, P. J., Concepción‐Zavaleta, M. J., Córdova, I. B. G., Dueñas, E. A. P., Quispe-Flores, M. A., Ramos-Yataco, A., Alcalde-Loyola, C., Massucco-Revoredo, F. G., Paz‐Ibarra, J., et al. (2022) · World Journal of Methodology · doi:10.5662/wjm.v12.i5.381 · Cited by 30
Preoperative assessment of nonfunctioning pancreatic endocrine tumours: role of MDCT and MRI
Foti, G., Boninsegna, L., Falconi, M., & Mucelli, R. P. (2013) · La radiologia medica · doi:10.1007/s11547-013-0956-5 · Cited by 24
REVIEWS IN BASIC AND CLINICAL GASTROENTEROLOGY
Lynch, J. P., Metz, D. C., Schuppan, D., Junker, Y., & Barisani, D. (2009) · Cited by 24
Dahdaleh, F. S., Calva‐Cerqueira, D., Carr, J. C., Liao, J., Mezhir, J. J., O’Dorisio, T. M., & Howe, J. R. (2011) · Annals of Surgical Oncology · doi:10.1245/s10434-011-1997-4 · Cited by 24
Pathologic research update of colorectal neuroendocrine tumors
Ni, S.-J., Sheng, W.-Q., & Du, X. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i14.1713 · Cited by 25
Imaging of Gastrointestinal Tract Ailments
Sun, B., Liu, J., Li, S., Lovell, J. F., & Zhang, Y. (2023) · Journal of Imaging · doi:10.3390/jimaging9060115 · Cited by 27
Chandra, P., Yarandi, S., Khazai, N. B., Jacobs, S., & Umpierrez, G. E. (2010) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e3181ee7be2 · Cited by 23
Li, Y., Liu, Z., Harwig, C., Pourghiasian, M., Lau, J., Lin, K., Schaffer, P. C., Bénard, F., & Perrin, D. M. (2013) · PubMed · Cited by 23
Nikolaou, A., Thomas, D., Kampanellou, C., Alexandraki, K., Andersson, L.-G., Sundín, A., & Kaltsas, G. (2010) · Journal of Endocrinological Investigation · doi:10.1007/bf03350344 · Cited by 23
Self-citationBuil‐Bruna, N., Dehez, M., Manon, A., Nguyen, T. X. Q., & Trocóniz, I. F. (2016) · The AAPS Journal · doi:10.1208/s12248-016-9884-3 · Cited by 23
Detection of Neuroendocrine Liver Metastases with MnDPDP-Enhanced MRI
Rockall, A., Planche, K., Power, N., Nowosinska, E., Monson, J., Grossman, A. B., & Reznek, R. H. (2008) · Neuroendocrinology · doi:10.1159/000176207 · Cited by 22
“Neuroendocrine tumours (NETs) are rare and vary in malignant potential depending on their cell type [”
BackgroundSelf-citationGrimaldi, F., Fazio, N., Attanasio, R., Frasoldati, A., Papini, E., Angelini, F., Baldelli, R., Berretti, D., Bianchetti, S., Bizzarri, G., et al. (2014) · Journal of Endocrinological Investigation · doi:10.1007/s40618-014-0119-0 · Cited by 23
“In less than 5 %, it can be caused by retroperitoneal or ovarian metastases that release serotonin or tachykinin, bypass the liver and enter the systemic circulation [179, 180, 181, 182].”
BackgroundTargeted Radionuclide Therapy for Neuroendocrine Tumours: Principles and Application
Druce, M. R., Lewington, V. J., & Grossman, A. B. (2009) · Neuroendocrinology · doi:10.1159/000227808 · Cited by 22
Self-citationDifferential Diagnosis and Management of Diarrhea in Patients with Neuroendocrine Tumors
Pusceddu, S., Rossi, R. E., Torchio, M., Prinzi, N., Niger, M., Coppa, J. C., Giacomelli, L., Sacco, R., Facciorusso, A., Corti, F., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9082468 · Cited by 22
Glinicki, P., Kapuścińska, R., & Jeske, W. (2010) · PubMed · Cited by 29
Grazzini, G., Danti, G., Cozzi, D., Lanzetta, M. M., Addeo, G., Falchini, M., Masserelli, A., Pradella, S., & Miele, V. (2018) · La radiologia medica · doi:10.1007/s11547-018-0946-8 · Cited by 21
Radioembolization in the Treatment of Neuroendocrine Tumor Metastases to the Liver
Vyleta, M. S., & Coldwell, D. M. (2011) · International Journal of Hepatology · doi:10.4061/2011/785315 · Cited by 21
“Hepatic tumor burden debulking appears to improve survival as well [28–32].”
BackgroundNautiyal, A., Jha, A. K., Mithun, S., & Rangarajan, V. (2022) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000001535 · Cited by 21
Pelage, J., Fohlen, A., Mitry, E., Lagrange, C., Beauchet, A., & Rougier, P. R. (2016) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-016-1535-7 · Cited by 21
“Neuroendocrine tumors (NETs) are rare neoplasms arising from amine precursor uptake and decarboxylating cells located in the gastrointestinal tract (enterochromaffin cells), the pancreas (islet cells), and lungs (Kulchitsky cells) [1].”
BackgroundDebono, M., Hon, L. Q., Bax, N., Blakeborough, A., & Newell-Price, J. D. C. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0019 · Cited by 21
“metastases, especially to the liver (1).”
Zagar, T. M., White, R. R., Willett, C. G., Tyler, D. S., Papavassiliou, P., Papalezova, K. T., Guy, C. D., Broadwater, G., Clough, R. W., & Czito, B. G. (2012) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2011.09.041 · Cited by 20
Differential Diagnosis of Diarrhea in Patients With Neuroendocrine Tumors
Eads, J. R., Reidy‐Lagunes, D. L., Soares, H. P., Chan, J. A., Anthony, L. B., Halfdanarson, T. R., Naraev, B. G., Wolin, E. M., Halperin, D. M., Li, D., et al. (2020) · Pancreas · doi:10.1097/mpa.0000000000001658 · Cited by 21
“Diagnosis may be confirmed by an elevated fasting vasoactive intestinal peptide level (>200 pg/mL) in the presence of secretory diarrheawith a high stool sodium concentration (characteristic of secretory diarrhea), and radiologic evidence of a pancreatic lesion.(14,18) Treatment includes aggressive fluid and electroly…”
BackgroundGiammarile, F., Billotey, C., Lombard‐Bohas, C., Bars, D. L., Bournaud, C., Masson, S., Walter, T., Houzard, C., Scoazec, J., Hervieu, V., et al. (2010) · Nuclear Medicine Communications · doi:10.1097/mnm.0b013e3283412143 · Cited by 19
Alexandraki, K., Tsoli, M., Kyriakopoulos, G., Angelousi, A. G., Nikolopoulos, G. K., Kolomodi, D., & Kaltsas, G. (2020) · Minerva Endocrinology · doi:10.23736/s0391-1977.19.03012-8 · Cited by 19
Self-citationHan, T., Cong, H., Yu, B., & Shen, Y. (2022) · BioFactors · doi:10.1002/biof.1875 · Cited by 20
“Therefore, the CPA4 page may be a potential biomarker of pancreatic cancer.(83) These studies describe the differences between pancreatic cancer and neighboring tissues from the perspective of peptidomics and provide new ideas HAN ET AL.”
BackgroundKos‐Kudła, B., Bolanowski, M., Handkiewicz-Junak, D., Jarząb, B., Królicki, L., Krzakowski, M. J., Kunikowska, J., Nasierowska-Guttmejer, A. M., Nowak, A. J., Rydzewska, G. M., et al. (2008) · PubMed · Cited by 19
Kaklamanos, M., Karoumpalis, I., Salla, C., Thomas, D., Kanakis, G., Alexandraki, K., Sougioultzis, S., Diakatou, E., Kontogeorgos, G., & Kaltsas, G. (2011) · Endocrine Related Cancer · doi:10.1530/erc-10-0191 · Cited by 19
“…and biopsy (FNAB) of pancreatic lesions can be easily performed during endoscopic ultrasonography (EUS), allowing for the preoperative cytological characterisation of such lesions and the estimation of biological behaviour through Ki-67 labelling index (LI) estimation (Kaltsas et al. 2004).”
InfluentialSelf-citationEndocrine Tumors of the Pancreas
Simon, P., Spilcke-Liss, E., & Wallaschofski, H. (2006) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2006.02.011 · Cited by 19
Papadogias, D., Makras, P., Kossivakis, K., Kontogeorgos, G., Piaditis, G. P., & Kaltsas, G. (2007) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e3282294d88 · Cited by 18
Self-citationHantel, C., Lewrick, F., Schneider, S. C., Zwermann, O., Perren, A. A., Reincke, M., Süss, R., & Beuschlein, F. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1980 · Cited by 18
Gastroenteropancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1
Tonelli, F., Giudici, F., Giusti, F., & Brandi, M. L. (2012) · Cancers · doi:10.3390/cancers4020504 · Cited by 18
“) syndrome [95].”
Koumarianou, A. A., Chatzellis, E., Boutzios, G., Tsavaris, N., & Kaltsas, G. (2013) · PubMed · Cited by 18
Self-citationEndocrine tumors: The evolving role of positron emission tomography in diagnosis and management
Naji, M., Hodolič, M., El-Refai, S., Khan, S., Marzola, M. C., Rubello, D., & AL-NAHHAS, A. M. (2009) · Journal of Endocrinological Investigation · doi:10.1007/bf03346550 · Cited by 18
Treatment of Pituitary Carcinomas and Atypical Pituitary Adenomas: A Review
HIROHATA, T., Ishii, Y., & Matsuno, A. (2014) · Neurologia medico-chirurgica · doi:10.2176/nmc.ra.2014-0178 · Cited by 17
Cidón, E. U. (2017) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v9.i1.4 · Cited by 17
Hendifar, A. E., Ramirez, R. A., Anthony, L. B., & Liu, E. (2019) · Pancreas · doi:10.1097/mpa.0000000000001391 · Cited by 17
Lanke, G., Stewart, J., & Lee, J. H. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i37.6322 · Cited by 17
Medical treatment of gastrinomas
Auernhammer, C. J., & Göke, B. (2007) · Wiener klinische Wochenschrift · doi:10.1007/s00508-007-0877-1 · Cited by 17
Retroperitoneal paraganglioma manifesting as paralytic ileus: a case report
Lin, W., Wang, H., Chang, C., Lin, J., & Tsai, C. (2012) · Journal of Medical Case Reports · doi:10.1186/1752-1947-6-158 · Cited by 17
“Nonfunctional paragangliomas most commonly manifest as abdominal pain or a mass [4].”
BackgroundPancreatic Neuroendocrine Tumor with Atypical Radiologic Presentation
Singh, R., Calhoun, S., Shin, M., & Katz, R. (2008) · Radiology Case Reports · doi:10.2484/rcr.v3i3.162 · Cited by 17
Diagnostics and treatment of insulinoma
KOREN, S. K. M. (2015) · Neoplasma · doi:10.4149/neo_2015_083 · Cited by 20
“Reported objective tumor response of these combinations ranges between 6 % to 70 % (average 25 – 40 %) and symptomatic response of about 50 % with duration of 20 – 24 months [107, 110, 111] Recently quite favourable results have been reported using as a first-line chemotherapy capecitabin with tenozolomid, achieving 7…”
BackgroundIslet Cell Carcinoma: Neuroendocrine Tumors of the Pancreas and Periampullary Region
Nakakura, E. K., & Bergsland, E. K. (2007) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2007.04.005 · Cited by 17
The role of serotonin inhibition within the treatment of carcinoid syndrome
George, J., Ramage, J. K., White, B. E., & Srirajaskanthan, R. (2023) · Endocrine Oncology · doi:10.1530/eo-22-0077 · Cited by 17
Phan, A. T., & Dave, B. (2016) · Cancer Medicine · doi:10.1002/cam4.742 · Cited by 16
“The aim of therapy for patients with advanced NET is to achieve tumor control through eradicating or stabilizing disease, prolonging survival, and relieving the symptoms of functional tumors, while improving patients’ overall functioning and maintaining their quality of life [5].”
BackgroundChang, T. S., Lin, H.-K., Rogers, K. A., Brame, L. S., Yeh, M. M., Yang, Q., & Fung, K.-M. A. (2013) · Europe PMC (PubMed Central) · Cited by 20
Metastatic Atypical Carcinoid Tumor of the Inferior Rectus Muscle
Kıratlı, H., Yılmaz, P. T., & Yildiz, Z. I. (2008) · Ophthalmic Plastic and Reconstructive Surgery · doi:10.1097/iop.0b013e31818b6d02 · Cited by 16
Epidemiology and Clinical Presentation
Davì, M. V., Toaiari, M., & Francia, G. (2012) · Updates in surgery/Updates in surgery series · doi:10.1007/978-88-470-2673-5_7 · Cited by 16
Stefàno, E., Castro, F. D., Ciccarese, A., Muscella, A., Marsigliante, S., Benedetti, M., & Fanizzi, F. P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168568 · Cited by 15
“…for neuroendocrine neoplasms are the gastroenteropancreatic (GEP) and bronchopulmonary (BP) tracts, although they can develop in any organ or system in the human body, with similar features due to their neuroendocrine nature (Figure and respiratory tracts in the di ff use endocrine system) [1,3].”
BackgroundSantos, A. P., Couto, C. F., Pereira, S. S., & Monteiro, M. P. (2022) · Neuroendocrinology · doi:10.1159/000522115 · Cited by 15
Abdel-Rahman, O. M., & Fouad, M. (2015) · Tumor Biology · doi:10.1007/s13277-015-3064-4 · Cited by 15
Pivonello, C., Rousaki, P., Negri, M., Sarnataro, M., Napolitano, M., Marino, F. Z., Patalano, R., Martino, M. C. D., Sciammarella, C., Faggiano, A., et al. (2016) · Endocrine · doi:10.1007/s12020-016-1079-2 · Cited by 15
Self-citationIntra-Arterial Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumor Liver Metastases
Ebbers, S. C., Barentsz, M. W., Braat, A. J. A. T., & Lam, M. G. E. H. (2019) · Digestive Disease Interventions · doi:10.1055/s-0038-1676300 · Cited by 15
Dosimetry in Lu-177-DOTATATE peptide receptor radionuclide therapy: a systematic review
Nautiyal, A., Michopoulou, S. K., & Guy, M. (2023) · Clinical and Translational Imaging · doi:10.1007/s40336-023-00589-x · Cited by 15
“Tumour sites, their radio-sensitivity, tumour volume, their microenvironment and proliferation rate are the other contributing factors [118, 119].”
Do glucagonomas always produce glucagon?
Albrechtsen, N. J. W., Challis, B., Damjanov, I., & Holst, J. J. (2016) · Biomolecules and Biomedicine · doi:10.17305/bjbms.2015.794 · Cited by 17
Bostan, H., Düğer, H., Akhanlı, P., Çalapkulu, M., Türkmenoğlu, T. T., Erdöl, A. K., Duru, S. A., Sencar, M. E., Kızılgül, M., Uçan, B., et al. (2021) · HORMONES · doi:10.1007/s42000-021-00316-z · Cited by 14
van, D. K. P., Mühlbauer, E., & Phi‐van, L. (2015) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2015.05.008 · Cited by 15
A stepwise approach to the management of metastatic midgut carcinoid tumor
Bhattacharyya, S., Gujral, D. M., Toumpanakis, C., Dreyfus, G., Davidson, B. R., Davar, J., & Caplin, M. E. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.70 · Cited by 14
“Interferon-α has a similar effect to somatostatin analogs on symptom control but is generally regarded as a second-line therapy owing to its adverse-effect profile”
BackgroundDiagnosis and therapy of carcinoid tumors—current state of the art and future directions
Khan, M. U., & Coleman, R. E. (2008) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2008.05.008 · Cited by 14
Mauro, A. D., Scognamiglio, G., Aquino, G., Cerrone, M., Liguori, G., Clemente, O., Bonito, M. D., Cantile, M., Botti, G., Tafuto, S., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22137049 · Cited by 14
“The term “neuro” is associated with the presence of dense core granules that are similar to those present in serotonergic neurons, which store monoamines, while the “endocrine” property refers to the synthesis and secretion of these monoamines [2].”
BackgroundTumeurs endocrines digestives : stratégie diagnostique
Mathonnet, M. (2007) · Journal de Chirurgie · doi:10.1016/s0021-7697(07)91954-7 · Cited by 14
Pelage, J., Fohlen, A., Mitry, E., Lagrange, C., Beauchet, A., & Rougier, P. R. (2017) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-017-1573-9 · Cited by 14
Liu, H., Li, J., Liang, C., Chu, Y., Wang, Y., Lv, L., Liu, D., & Tan, Y. (2024) · Surgical Endoscopy · doi:10.1007/s00464-024-10706-0 · Cited by 13
“Neuroendocrine neoplasms (NENs) are a group of different types of tumors that can occur anywhere in the body where neuroendocrine cells are present, including endocrine glands, endocrine cells with gland tissues, and endocrine cells of digestive and respiratory tracts [1].”
Cheng, C., Pan, L., Dimitrakopoulou‐Strauss, A., Schäfer, M. K.-H., Wängler, C., Wängler, B., Haberkorn, U., & Strauss, L. G. (2011) · EJNMMI Research · doi:10.1186/2191-219x-1-34 · Cited by 13
“NETs originate mostly from the gastroenteropancreatic tract and express specific receptors like amine and peptide receptors (somatostatin, vasointestinal peptide receptors, bombesin, cholecystokinin, gastrin and/or substance P) [33].”
BackgroundSerotoninergic brain dysfunction in neuroendocrine tumor patients: A scoping review
Salvia, A. L., Pomeri, A. P., Persano, I., Trevisi, E., Parlagreco, E., Colombi, N., Brizzi, M. P., Picci, R. L., & Oliva, F. (2021) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2021.152244 · Cited by 13
“The diagnosis of these syndromes is established when a specific combination of signs and symptoms matches the clinical presentation of a patient and confirmed once corresponding elevated hormone levels are established [4].”
BackgroundDavì, M. V., Bodei, L., Ferdeghini, M., Falconi, M., Testoni, M., Paganelli, G., Oliani, C., Cascio, V. L., & Francia, G. (2008) · Endocrine Practice · doi:10.4158/ep.14.2.213 · Cited by 13
Örlefors, H., Sundin, A., Eriksson, B. K., Skogseid, B. M., Öberg, K., Åkerström, G., & Hellman, P. (2012) · Cancers · doi:10.3390/cancers4010100 · Cited by 13
“Anatomical imaging by computed tomography (CT) and magnetic resonance imaging (MRI) still forms the basis for tumour visualization, but cannot always visualize smaller tumours [6,7].”
MethodShin, Y., Ha, S. Y., Hyeon, J., Lee, B., Lee, J., Jang, K., Kim, K.-M., Park, Y. S., & Park, C.-K. (2015) · Cancer Research and Treatment · doi:10.4143/crt.2014.224 · Cited by 13
Insulinoma: case report and review of diagnostic and treatment modalities.
Patel, S., Narwari, M., Parekh, D., & Shah, V. (2013) · PubMed · Cited by 13
Biochemical Testing for Neuroendocrine Tumors
Vinik, A. I., & Silva, M. P. (2009) · Springer eBooks · doi:10.1007/978-1-4419-1069-1_26 · Cited by 14
Functioning neuroendocrine tumors (NET): Minimum requirements for a NET specialist
Spada, F., Rossi, R. E., Modica, R., Gelsomino, F., Rinzivillo, M., Rubino, M., Pisa, E., Salvia, A. L., & Fazio, N. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.102907 · Cited by 12
Yazdanpanah, O., Surapaneni, S., Shanah, L., & Kabashneh, S. (2021) · Cureus · doi:10.7759/cureus.14006 · Cited by 13
“They have dense core granules similar to the granules containing monoamines present in serotonergic neurons and they have the ability to synthesize and secrete monoamines [1,2].”
BackgroundDrug Development in Neuroendocrine Tumors: What Is on the Horizon?
García‐Álvarez, A., Cubero, J. H., & Capdevila, J. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00834-3 · Cited by 12
PET/Computed Tomography in Neuroendocrine Tumor
Shamim, S. A., Kumar, A., & Kumar, R. (2015) · PET Clinics · doi:10.1016/j.cpet.2015.03.005 · Cited by 12
Tailored imaging of islet cell tumors of the pancreas amidst increasing options
Fiebrich, H., van Asselt, S. J., Brouwers, A. H., van Dullemen, H. M., Pijl, M. E. J., Elsinga, P. H., Links, T. P., & de Vries, E. G. E. (2011) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2011.05.006 · Cited by 12
“Patients with an islet cell tumor have a chance of –30%, depending on the subtype of islet cell tumor, that n underlying genetic predisposition is present [6].”
BackgroundVatsadze, S. Z., Eremina, O. E., Veselova, I. A., Kalmykov, S. N., & Nenajdenko, V. G. (2017) · Russian Chemical Reviews · doi:10.1070/rcr4752 · Cited by 13
Garona, J., Pífano, M., Ripoll, G. V., & Alonso, D. F. (2020) · Vitamins and hormones · doi:10.1016/bs.vh.2019.08.010 · Cited by 13
Igaz, P. (2009) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-1664-8_1 · Cited by 12
Carcinoid tumor and intravenous octreotide infusion during labor and delivery
Le, B., Bharadwaj, S., & Malinow, A. M. (2009) · International Journal of Obstetric Anesthesia · doi:10.1016/j.ijoa.2008.10.005 · Cited by 12
Sahoo, M. K., Gupta, S., Singh, I., Pahwa, S. S., Durgapal, P., & Bal, C. S. (2012) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.12048 · Cited by 12
EZH2 Expression in Intestinal Neuroendocrine Tumors
Faviana, P., Marconcini, R., Ricci, S., Galli, L., Lippolis, P. V., Farci, F., Castagna, M., & Boldrini, L. (2018) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000647 · Cited by 13
New Treatments for the Carcinoid Syndrome
Loughrey, P. B., Zhang, D., & Heaney, A. P. (2018) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2018.04.014 · Cited by 12
Sholi, A. N., Gray, K. D., & Pomp, A. (2019) · BMJ Case Reports · doi:10.1136/bcr-2019-229414 · Cited by 12
Medical Treatment of Gastrointestinal Neuroendocrine Neoplasms
Tsoli, M., Alexandraki, K., Xanthopoulos, C., Kassi, E. N., & Kaltsas, G. (2020) · Hormone and Metabolic Research · doi:10.1055/a-1110-7251 · Cited by 13
“Zollinger–Ellison syndrome, secondary to hypersecretion of gastrin from a duodenal or pancreatic NEN may occur sporadically or in approximately 25–30 % of cases in the context of multiple endocrine neoplasia type 1 (MEN1) syndrome [5, 70].”
BackgroundSelf-citationCommentary: imaging of islet-cell tumours.
Grossman, A. B., & Reznek, R. H. (2005) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2004.11.002 · Cited by 11
Self-citationCyclooxygenase-2 expression in gastroenteropancreatic neuroendocrine tumors.
İnce, A. T., Ovünç, O., Celikel, C. A., Göksel, S., Tosun, S., & Peker, O. (2007) · PubMed Central · doi:10.12659/msm.912419 · Cited by 11
Advancements in Neuroendocrine Neoplasms: Imaging and Future Frontiers
Asmundo, L., Rizzetto, F., Blake, M. A., Anderson, M., Mojtahed, A., Bradley, W. R., Shenoy‐Bhangle, A. S., Castillo, C. F. F.-D., Qadan, M., Ferrone, C. R., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13113281 · Cited by 11
Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., Yalçın, Ş., Çoban, E., Evrensel, T., Kalkan, Z., et al. (2023) · The Oncologist · doi:10.1093/oncolo/oyad257 · Cited by 11
“Median (min-max) 6 (1-64) 6 (1-64) 6 (1-39) 6 (2-21)”
Chmiel, P., Rychcik-Pazyrska, P., & Stec, R. (2023) · Cancers · doi:10.3390/cancers15215232 · Cited by 11
“In grouped recent years, the incidence of GEP-NETs has been constantly increasing from 1.09 per 100,000 in 1973 to 6.98 per 100,000 in 2012, which makes them the second most common digestive cancer [6,7].”
BackgroundMethodInfluentialKaltsas, G., & Grossman, A. B. (2015) · Clinical Endocrinology · doi:10.1111/cen.12831 · Cited by 11
Self-citation
Metadata
- Authors
- Kaltsas, G. A., Besser, G. M., & Grossman, A. B.
- Affiliations
- St Bartholomew's Hospital (GB)
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2004-06-01
- Volume
- 25
- Issue
- 3
- Pages
- 458-511
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W2031301095
- Semantic Scholar
- b09a37699a89446c4662f1bc87eb975bf31118b7
- Cited by
- 674
- References
- 670
- Citations by year
- 2026: 4 · 2025: 19 · 2024: 17 · 2023: 26 · 2022: 17 · 2021: 23 · 2020: 23 · 2019: 24 · 2018: 31 · 2017: 27 · 2016: 34 · 2015: 46 · 2014: 30 · 2013: 37 · 2012: 49
- FWCI
- 4.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrine Reviews (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Keywords
- neuroendocrine tumors, diagnosis, tumor markers, endocrine syndromes, somatostatin analogues, MIBG scintigraphy, endoscopic ultrasound, interferon-alpha, chemotherapy, radionuclide therapy, multimodal therapy, quality of life
- MeSH terms
- Adrenal Gland Neoplasms, Animals, Antineoplastic Combined Chemotherapy Protocols, Gastrointestinal Neoplasms, Humans, Pancreatic Neoplasms, Parathyroid Neoplasms, Pituitary Neoplasms, Prognosis, Quality of Life, Sensitivity and Specificity, Somatostatin, Thyroid Neoplasms, Tomography, X-Ray Computed, Biomarkers, Tumor, Interferon-alpha, Carcinoma, Neuroendocrine, Neuroendocrine Tumors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.